Displaying 1-4 of 4 key documents
Source: Malaria Journal | April 2012
This review paper explores documented episodes of malaria resurgence worldwide, and assesses their association with malaria control programmes, a higher risk of disease transmission and drug resistance. It identifies 75 instances of resurgence in 61 countries over a period of 70 years, with the vast majority related to weakening control programmes, usually due to limited resources. This suggests that gains in malaria control can be lost rapidly if support is not sustained. The authors argue that finding ways to sustain funding for control programmes is crucial, and that there is an urgent need to develop practical solutions to operational and technical threats to their success.
Source: Open AIDS Journal
This series of articles considers the questions and conflicts surrounding the use of patent pools for antiretroviral (ARV) treatments for HIV/AIDS.
It provides background to the debate, considers individual proposals including the UNITAID patent pool, and offers regional perspectives on the suitability of patent pools to Africa, China and India.
Source: The Lancet | October 2008
This series of commentaries and research articles — published by The Lancet, the Peking University Health Sciences Centre and the China Medical Board — addresses China's major health challenges, strategies and future. It has been produced by a group of 63 scientists from 10 countries with Chinese scientists making up two-thirds of the authors.
The research papers give scientific evidence on key health issues including the emergence and control of both infectious and chronic non-infectious diseases in China as well as the performance of China's healthcare system.
Authors of the series' commentaries further discuss a range of topical issues affecting China's health system, including the state of biomedical science and technology (see 'Progress in Chinese biomedicine a massive challenge'), medical research ethics, the lessons learnt from China's schistosomiasis control programme and the challenges the country faces in controlling HIV/AIDS.
Source: PLoS Medicine | June 2007
Schizophrenia is relatively rare — affecting 1% of the world's population — but is arguably one of the most severe mental illnesses. Diagnosing and treating it can be hard enough in developed countries; the challenges are magnified in developing nations with inadequate health systems; few trained staff; and pervasive social stigma. So how best to treat it? In this debate, three psychiatrists offer their different viewpoints.
Vikram Patel, at the London School of Hygiene and Tropical Medicine, says the shortage of mental health specialists means that the most effective way of spreading the expertise around might be for non-specialist health workers or community representatives to be trained to bear the brunt of providing first-line mental health services. Saeed Farooq, at Pakistan's Lady Reading Hospital, argues that the principles of the WHO's DOTS TB programme, in which patients are given an uninterrupted supply of medication taken under close supervision, could be used to treat schizophrenia. The rationale is that missing medication for schizophrenia, which can be common given the cognitive impairment associated with the illness, has serious consequences and can lead to much higher risks of relapse. R. Thara, director of the Schizophrenia Research Foundation, Chennai, India, advocates tackling stigma by offering proper treatment. In India at least, he says, the mystification of mental illness is intensified by a lack of awareness about schizophrenia and also by "magico-religious" beliefs. Effective treatment that shows the symptoms to be an illness rather than a religious curse is the best antidote to stigma, he says.